Tetra Bio-Pharma Gets Regulatory Approval for Phase 2 Cannabis Oil Trial

- January 29th, 2018

Tetra Bio-Pharma announced it obtained Health Canada approval for their phase 2 clinical trial investigating the safety and efficacy of different “doses and ratios” of medical cannabis oil treating chronic pain.

Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) announced it obtained Health Canada approval for their phase 2 clinical trial investigating the safety and efficacy of different “doses and ratios” of medical cannabis oil treating chronic pain.
As quoted in the press release:

“To our knowledge, this is the first Health Canada-approved phase 2, randomized, double-blind, placebo-controlled clinical trial using encapsulated medical cannabis oil in Canada,” said Bernard Fortier, Tetra Bio-Pharma’s CEO. According to an Eight Capital analysis1, the cannabis oil market is expected to reach 1.5B$ in 2024.
“This is a significant milestone in our mission to become a global bio-pharmaceutical leader in cannabinoids-based drug development. We currently have a strong pipeline of five cannabinoid-based products, all launched last year and using different delivery systems, in various stages towards Health Canada and FDA approval.”
The Phase 2 trial will be conducted with Montreal-based Santé Cannabis, Quebec’s first medical clinic and resource centre specializing in cannabis and cannabinoids for medical purposes.

Click here to read the full press release.

Get the latest Cannabis Investing stock information

Get the latest information about companies associated with Cannabis Investing Delivered directly to your inbox.

Cannabis Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *